Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche for the buyout

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Oct 28, 2023 9:41am

166 Views

Post# 35705558

RE:RE:RE:RE:Roche for the buyout

I'm sure it'll be Roche to jump in at some pt, but I see an argument for Merck as well. The cheer squad will have you thinking every major under the sun is just throwing offers at Oncy in desperate attempts to outbid each other. That is certainly not clear, but what is clear is that Azz had to create a 2nd account (peladawn...lol) so someone would finally support his "arguments."

<< Previous

Bullboard Posts

Next >>

NTG Clarity Networks' growth story continues with $22M contract